Detecting Beta-amyloid in the Retina
Non-invasive Retinal Imaging to Detect Beta-amyloid in Alzheimer's Disease
Sponsor: Center for Eye Research Australia
Terminated
This study has been transferred to the Human Research Ethics Committee of St Vincent's Hospital Melbourne.
Other terminated trials from Center for Eye Research Australia
Other Alzheimer Disease trials with similar outcome
Listed as NCT07529912, this observational or N/A phase trial focuses on Alzheimer Disease and Dementia and remains terminated or withdrawn. Sponsored by Center for Eye Research Australia, it has been updated 2 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)The study involves retinal imaging using specialised cameras to capture detailed photographs of the eye. Imaging includes the use of two hyperspectral retinal cameras, which are similar to standard retinal cameras but use multi-wavelength (multicoloured) light instead of a conventional white-light flash.
These hyperspectral imaging devices are investigational and are not approved for routine clinical use in Australia. Their use in this research has been approved by the Human Research Ethics Committee of the Royal Victorian Eye and Ear Hospital following scientific and ethical review. The Therapeutic Goods Administration of Australia has been notified of their use under the Clinical Trial Notification (CTN) scheme.
The study involves retinal imaging using specialised cameras to capture detailed photographs of the eye. Imaging includes the use of two hyperspectral retinal cameras, which are similar to standard retinal cameras but use multi-wavelength (multicoloured) light instead of a conventional white-light flash.
These hyperspectral imaging devices are investigational and are not approved for routine clinical use in Australia. Their use in this research has been approved by the Human Research Ethics Committee of the Royal Victorian Eye and Ear Hospital following scientific and ethical review. The Therapeutic Goods Administration of Australia has been notified of their use under the Clinical Trial Notification (CTN) scheme.
Status Flow
Change History
2 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
-
Apr 16, 2026 — Apr 28, 2026 [daily]
Terminated
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides detailed information about retinal structure. Previous research has demonstrated a potential role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. This study aims to further evaluate the use of hyperspectral retinal imaging in the assessment of individuals with dementia or those at risk of Alzheimer's disease.
Contact Information
- Center for Eye Research Australia
For direct contact, visit the study record on ClinicalTrials.gov .